Quality assured; sample to interpretation

Registration now open for Molecular Pathology, Pharmacogenetics, Pre and Post-Natal Testing, POCT, and Technical EQA schemes.

Download our catalogue

Our 2025 catalogue is now live!

We have made several changes to our schemes based on your feedback. View our 2025 catalogue and register for your scheme today!

EMQN launches new EQA scheme for MT-RNR1 Point-of-Care Testing (POCT) for use with the Genedrive® MT-RNR1 ID Kit

Why choose an External Quality Assessment (EQA) or proficiency test (PT) in molecular diagnostics?

Assure quality | Prevent errors | Interpret correctly

As a molecular diagnostics service provider, you want to be sure that you offer the best possible service. This is where EQAs can provide a wide range of benefits, whether you’re a hospital laboratory or a private testing company:

Regulatory compliance and accreditation
Quality assurance & risk mitigation
Objective evidence
Standardisation & harmonisation
Continuous professional evaluation & development
Relied on by patients and treating physicians

Look no further:
EMQN offers more than just assessment!

EMQN is leading global provider of quality assurance tools and knowledge to the human molecular pathology and genomics testing community. Our network of highly experienced assessors will guide you to diagnostic excellence.

The best schemes and assessments

EMQN offers External Quality Assessment (EQA) schemes, also referred to as proficiency tests (PT). But we go far beyond simply selling these schemes.

EMQN’s EQA schemes are designed and developed to test the whole analytical process of a molecular diagnostics laboratory, from sample, through testing and interpretation, to final report.

For each EQA we provide at least two expert peer assessors who will meticulously evaluate your ability to interpret your results in relation to mock clinical referral information, as well as assessing the clarity and accuracy of your final report.

Participation means you can rest assured you are providing the best possible clinical diagnostic procedures, analytical performance, and clinical interpretation.

The best support and knowledge

Additional support

Our services don’t stop at administering schemes, we are also available for additional support and guidance to assist you in optimising your procedures.

Knowledge leaders

EMQN’s community comprises an extensive peer group assessor base and network of key opinion leaders who are committed to regularly publishing best practice guidelines. This unique collaboration of experts takes pride in offering true knowledge leadership to the molecular diagnostics field.

Hear from our customers / collaborators

EMQN represents a global standard and benchmark for high-quality molecular diagnostics – powered by leading experts throughout Europe and the world. With their support, we are able to ensure end-to-end process quality control that promotes trust and excellence in our mission to provide data-driven, life-changing answers to patients globally.

Prof. Peter Bauer, Chief Medical and Genomic OfficerCENTOGENE

EMQN exemplifies professionalism and expertise in all their services. They are not just a provider, but a valuable partner in improving the quality of genetic testing in the laboratory.

Dr Artur Kowalik, Department of Molecular DiagnosticsHoly Cross Cancer Center, Kielce, Poland

SydPath has been working synergistically with EMQN for many years now. We highly value the support in ensuring our diagnostic genomic laboratory test results are accurate, reliable, and comparable. This allows us to honour our commitment of assuring our results are actionable and clinically meaningful to the clinicians and patients we serve and assists them in delivering optimised personalised therapeutic approaches.

Associate Professor Min Ru Qiu, Anatomical Pathology, Cytopathology & HistopathologySydPath, St Vincent's Hospital, Sydney